Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Kyowa Hakko Bio Co., Ltd. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters are spread across 4 examiners and 4 art units, so each reported action is associated with a separate examination assignment. This structure favors matter-specific response planning rather than assuming that one examiner’s approach will apply across the portfolio.
ARMATO JR, DENNIS IGNATIUS is the busiest examiner, with 1 pending matter. Because the busiest examiner does not hold multiple matters, the docket has no reported examiner concentration. Counsel should coordinate filing deadlines and substantive positions across the four assignments while preserving the distinctions among their art-unit settings.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (50%) |
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARMATO JR, DENNIS IGNATIUS | 1 | 42.9% | +80.0% |
| KOMATSU, LI N | 1 | 59.8% | +71.0% |
| OGUNBIYI, OLUWATOSIN A | 1 | 63.8% | +41.2% |
| DABKOWSKI, ERINNE R | 1 | 55.8% | +68.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18549804 | COMPOSITION AND AMELIORATING AGENT HAVING INFLAMMATION REDUCING EFFECT | OGUNBIYI, OLUWATOSIN A | 120d overdue |
| 18699491 | MICROORGANISM HAVING ABILITY TO PRODUCE N-ACETYLNEURAMINIC ACID AND/OR N-ACETYLNEURAMINIC ACID-CONTAINING CARBOHYDRATE AND METHOD FOR PRODUCING N-ACETYLNEURAMINIC ACID AND/OR N-ACETYLNEURAMINIC ACID-CONTAINING CARBOHYDRATE USING SAID MICROORGANISM | ARMATO JR, DENNIS IGNATIUS | 41d |
| 18570198 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ACUTE RENAL FAILURE | KOMATSU, LI N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18549804 | COMPOSITION AND AMELIORATING AGENT HAVING INFLAMMATION REDUCING EFFECT | OGUNBIYI, OLUWATOSIN A | 120d overdue |
| 16617497 | USE OF CITRULLINE AND GLUTATHIONE TO INCREASE MUSCLE MASS | DABKOWSKI, ERINNE R | 78d overdue |
| 18699491 | MICROORGANISM HAVING ABILITY TO PRODUCE N-ACETYLNEURAMINIC ACID AND/OR N-ACETYLNEURAMINIC ACID-CONTAINING CARBOHYDRATE AND METHOD FOR PRODUCING N-ACETYLNEURAMINIC ACID AND/OR N-ACETYLNEURAMINIC ACID-CONTAINING CARBOHYDRATE USING SAID MICROORGANISM | ARMATO JR, DENNIS IGNATIUS | 41d |
| 18570198 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ACUTE RENAL FAILURE | KOMATSU, LI N | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1658 | 1 |
| 1645 | 1 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18699491 | MICROORGANISM HAVING ABILITY TO PRODUCE N-ACETYLNEURAMINIC ACID AND/OR N-ACETYLNEURAMINIC ACID-CONTAINING CARBOHYDRATE AND METHOD FOR PRODUCING N-ACETYLNEURAMINIC ACID AND/OR N-ACETYLNEURAMINIC ACID-CONTAINING CARBOHYDRATE USING SAID MICROORGANISM | ARMATO JR, DENNIS IGNATIUS | 1651 | §101§102§112 | Non-Final OA | 41d | Pending | Apr 08, 2024 |
| 18570198 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR ACUTE RENAL FAILURE | KOMATSU, LI N | 1658 | §103§112Other | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18549804 | COMPOSITION AND AMELIORATING AGENT HAVING INFLAMMATION REDUCING EFFECT | OGUNBIYI, OLUWATOSIN A | 1645 | §101§102§112Other | Non-Final OA | 120d overdue | Pending | Sep 08, 2023 |
| 16617497 | USE OF CITRULLINE AND GLUTATHIONE TO INCREASE MUSCLE MASS | DABKOWSKI, ERINNE R | 1654 | §103 | Final Rejection | 78d overdue | Pending | Nov 26, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKyowa Hakko Bio Co., Ltd. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Dennis Ignatius Armato Jr. has the most, with 1 of Kyowa Hakko Bio Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
